Important Safety Information

• The most common adverse reactions recorded during clinical trials with Reconcile^® were calm or lethargy, reduced appetite, vomiting, shaking, diarrhea, restlessness, excessive vocalization, aggression, and, in infrequent cases, seizures.
• Reconcile^® chewable tablets are contraindicated for dogs with epilepsy or a history of seizures; with drugs that lower the seizure threshold; with a monoamine oxidase inhibitor (MAOI) or within a minimum of 14 days of discontinuing therapy with an MAOI; in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs.
• A six week washout interval should be observed following discontinuation of therapy with Reconcile^® chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.
• For full product label, including complete safety information, click here.